Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 5/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | GLP1R | P43220 | 8/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21016081 | 0.91 | FAAH (0.45) | TSHRFAAHALDH1A1 | |
| SCHEMBL14996240 | 0.89 | TSHR (0.43) | TSHRFAAHALDH1A1 | |
| SCHEMBL22473696 | 0.88 | TSHR (0.42) | EPHX2TSHRFAAHGLP1RALDH1A1 | |
| SCHEMBL21106554 | 0.87 | EPHX2 (0.45) | EPHX2TSHRFAAHGLP1RRECQL | |
| SCHEMBL23568885 | 0.87 | EPHX2 (0.48) | EPHX2TSHRFAAHGLP1RRECQL | |
| SCHEMBL25729686 | 0.86 | EPHX2 (0.43) | EPHX2TSHRFAAHGLP1RRECQL | |
| SCHEMBL22861655 | 0.85 | KMT2A (0.42) | EPHX2TSHRFAAHGLP1RRECQL | |
| SCHEMBL23696006 | 0.85 | KMT2A (0.42) | EPHX2TSHRFAAHGLP1RRECQL | |
| SCHEMBL25591284 | 0.85 | EPHX2 (0.43) | EPHX2TSHRFAAHGLP1RRECQL | |
| SCHEMBL23945207 | 0.85 | MEN1 (0.53) | EPHX2GLP1RRECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11807636-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-11707457-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| EP-4194457-A1 | COMPOUND FOR TARGETING AND DEGRADING PROTEIN, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Leadingtac Pharmaceutical Co., Ltd. (CN) | 2023-06-14 | — | — | EP | disclosed |
| US-11352350-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-20210323952-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2021-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11352350-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | EPHX2 1890/4885TSHR 3319/4885FAAH 1771/4885 |
| US-20210323952-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | EPHX2 1890/4885TSHR 3319/4885FAAH 1771/4885 |
| US-11807636-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | EPHX2 1890/4885TSHR 3319/4885FAAH 1771/4885 |
| US-11707457-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | EPHX2 1890/4885TSHR 3319/4885FAAH 1771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.